APO Research
Talk to an analyst

APO RESEARCH · REPORT

Amyloidosis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Amyloidosis Therapeutics Market Analysis and Forecast 2026-2032

22 December 2025196 pages

Choose your research edition.

Industry ResearchAmyloidosis Therapeutics Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Amyloidosis Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Amyloidosis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Amyloidosis Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Amyloidosis Therapeutics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Amyloidosis Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Amyloidosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Amyloidosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Amyloidosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Amyloidosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Amyloidosis Therapeutics include Pfizer Inc., GlaxoSmithKline Plc, SOM Innovation Biotech SL, Prothena Corporation Plc, ProteoTech, Inc., Onyx Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc. and Celgene Corporation, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Amyloidosis Therapeutics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Amyloidosis Therapeutics, also provides the sales of main regions and countries. Of the upcoming market potential for Amyloidosis Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Amyloidosis Therapeutics sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Amyloidosis Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Amyloidosis Therapeutics sales, projected growth trends, production technology, application and end-user industry.

Amyloidosis Therapeutics Segment by Company

Pfizer Inc.

GlaxoSmithKline Plc

SOM Innovation Biotech SL

Prothena Corporation Plc

ProteoTech, Inc.

Onyx Pharmaceuticals, Inc.

Millennium Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc.

Celgene Corporation

Bsim2

Bellus Health Inc.

Arcturus Therapeutics, Inc

Alnylam Pharmaceuticals, Inc.

Amyloidosis Therapeutics Segment by Type

Canakinumab

CAEL-101

ALN-TTRsc02

ALN-ANG

AG-10

Others

Amyloidosis Therapeutics Segment by Application

ATTR Amyloidoses

AL Amyloidosis

AA Amyloidoses

Others

Amyloidosis Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyloidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Amyloidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyloidosis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Amyloidosis Therapeutics in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Amyloidosis Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Amyloidosis Therapeutics sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Amyloidosis Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Canakinumab Major Manufacturers Table 3. CAEL-101 Major Manufacturers Table 4. ALN-TTRsc02 Major Manufacturers Table 5. ALN-ANG Major Manufacturers Table 6. AG-10 Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Amyloidosis Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. ATTR Amyloidoses Major Manufacturers Table 10. AL Amyloidosis Major Manufacturers Table 11. AA Amyloidoses Major Manufacturers Table 12. Others Major Manufacturers Table 13. Amyloidosis Therapeutics Industry Trends Table 14. Amyloidosis Therapeutics Industry Drivers Table 15. Amyloidosis Therapeutics Industry Opportunities and Challenges Table 16. Amyloidosis Therapeutics Industry Restraints Table 17. Global Amyloidosis Therapeutics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Amyloidosis Therapeutics Revenue by Region (2021-2026) & (US$ Million) Table 19. Global Amyloidosis Therapeutics Revenue by Region (2027-2032) & (US$ Million) Table 20. Global Amyloidosis Therapeutics Revenue Market Share by Region (2021-2026) Table 21. Global Amyloidosis Therapeutics Revenue Market Share by Region (2027-2032) Table 22. Global Amyloidosis Therapeutics Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 23. Global Amyloidosis Therapeutics Sales by Region (2021-2026) & (k units) Table 24. Global Amyloidosis Therapeutics Sales by Region (2027-2032) & (k units) Table 25. Global Amyloidosis Therapeutics Sales Market Share by Region (2021-2026) Table 26. Global Amyloidosis Therapeutics Sales Market Share by Region (2027-2032) Table 27. Global Amyloidosis Therapeutics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Amyloidosis Therapeutics Revenue Market Share by Manufacturers (2021-2026) Table 29. Global Amyloidosis Therapeutics Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Amyloidosis Therapeutics Sales Market Share by Manufacturers (2021-2026) Table 31. Global Amyloidosis Therapeutics Sales Price (US$/unit) of Manufacturers (2021-2026) Table 32. Global Amyloidosis Therapeutics Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global Amyloidosis Therapeutics Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global Amyloidosis Therapeutics Manufacturers, Product Type & Application Table 35. Global Amyloidosis Therapeutics Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global Amyloidosis Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global Amyloidosis Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Amyloidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Amyloidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Amyloidosis Therapeutics Revenue Market Share by Type (2021-2026) Table 42. Global Amyloidosis Therapeutics Revenue Market Share by Type (2027-2032) Table 43. Global Amyloidosis Therapeutics Sales by Type 2021 VS 2025 VS 2032 (k units) Table 44. Global Amyloidosis Therapeutics Sales by Type (2021-2026) & (k units) Table 45. Global Amyloidosis Therapeutics Sales by Type (2027-2032) & (k units) Table 46. Global Amyloidosis Therapeutics Sales Market Share by Type (2021-2026) Table 47. Global Amyloidosis Therapeutics Sales Market Share by Type (2027-2032) Table 48. Global Amyloidosis Therapeutics Price by Type (2021-2026) & (US$/unit) Table 49. Global Amyloidosis Therapeutics Price by Type (2027-2032) & (US$/unit) Table 50. Global Amyloidosis Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Amyloidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 52. Global Amyloidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 53. Global Amyloidosis Therapeutics Revenue Market Share by Application (2021-2026) Table 54. Global Amyloidosis Therapeutics Revenue Market Share by Application (2027-2032) Table 55. Global Amyloidosis Therapeutics Sales by Application 2021 VS 2025 VS 2032 (k units) Table 56. Global Amyloidosis Therapeutics Sales by Application (2021-2026) & (k units) Table 57. Global Amyloidosis Therapeutics Sales by Application (2027-2032) & (k units) Table 58. Global Amyloidosis Therapeutics Sales Market Share by Application (2021-2026) Table 59. Global Amyloidosis Therapeutics Sales Market Share by Application (2027-2032) Table 60. Global Amyloidosis Therapeutics Price by Application (2021-2026) & (US$/unit) Table 61. Global Amyloidosis Therapeutics Price by Application (2027-2032) & (US$/unit) Table 62. Pfizer Inc. Company Information Table 63. Pfizer Inc. Business Overview Table 64. Pfizer Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 65. Pfizer Inc. Amyloidosis Therapeutics Product Portfolio Table 66. Pfizer Inc. Recent Development Table 67. GlaxoSmithKline Plc Company Information Table 68. GlaxoSmithKline Plc Business Overview Table 69. GlaxoSmithKline Plc Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. GlaxoSmithKline Plc Amyloidosis Therapeutics Product Portfolio Table 71. GlaxoSmithKline Plc Recent Development Table 72. SOM Innovation Biotech SL Company Information Table 73. SOM Innovation Biotech SL Business Overview Table 74. SOM Innovation Biotech SL Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. SOM Innovation Biotech SL Amyloidosis Therapeutics Product Portfolio Table 76. SOM Innovation Biotech SL Recent Development Table 77. Prothena Corporation Plc Company Information Table 78. Prothena Corporation Plc Business Overview Table 79. Prothena Corporation Plc Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Prothena Corporation Plc Amyloidosis Therapeutics Product Portfolio Table 81. Prothena Corporation Plc Recent Development Table 82. ProteoTech, Inc. Company Information Table 83. ProteoTech, Inc. Business Overview Table 84. ProteoTech, Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. ProteoTech, Inc. Amyloidosis Therapeutics Product Portfolio Table 86. ProteoTech, Inc. Recent Development Table 87. Onyx Pharmaceuticals, Inc. Company Information Table 88. Onyx Pharmaceuticals, Inc. Business Overview Table 89. Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio Table 91. Onyx Pharmaceuticals, Inc. Recent Development Table 92. Millennium Pharmaceuticals, Inc. Company Information Table 93. Millennium Pharmaceuticals, Inc. Business Overview Table 94. Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio Table 96. Millennium Pharmaceuticals, Inc. Recent Development Table 97. Isis Pharmaceuticals, Inc. Company Information Table 98. Isis Pharmaceuticals, Inc. Business Overview Table 99. Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio Table 101. Isis Pharmaceuticals, Inc. Recent Development Table 102. Celgene Corporation Company Information Table 103. Celgene Corporation Business Overview Table 104. Celgene Corporation Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Celgene Corporation Amyloidosis Therapeutics Product Portfolio Table 106. Celgene Corporation Recent Development Table 107. Bsim2 Company Information Table 108. Bsim2 Business Overview Table 109. Bsim2 Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Bsim2 Amyloidosis Therapeutics Product Portfolio Table 111. Bsim2 Recent Development Table 112. Bellus Health Inc. Company Information Table 113. Bellus Health Inc. Business Overview Table 114. Bellus Health Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Bellus Health Inc. Amyloidosis Therapeutics Product Portfolio Table 116. Bellus Health Inc. Recent Development Table 117. Arcturus Therapeutics, Inc Company Information Table 118. Arcturus Therapeutics, Inc Business Overview Table 119. Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Portfolio Table 121. Arcturus Therapeutics, Inc Recent Development Table 122. Alnylam Pharmaceuticals, Inc. Company Information Table 123. Alnylam Pharmaceuticals, Inc. Business Overview Table 124. Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio Table 126. Alnylam Pharmaceuticals, Inc. Recent Development Table 127. North America Amyloidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Amyloidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Amyloidosis Therapeutics Sales by Type (2021-2026) & (k units) Table 130. North America Amyloidosis Therapeutics Sales by Type (2027-2032) & (k units) Table 131. North America Amyloidosis Therapeutics Sales Price by Type (2021-2026) & (US$/unit) Table 132. North America Amyloidosis Therapeutics Sales Price by Type (2027-2032) & (US$/unit) Table 133. North America Amyloidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 134. North America Amyloidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 135. North America Amyloidosis Therapeutics Sales by Application (2021-2026) & (k units) Table 136. North America Amyloidosis Therapeutics Sales by Application (2027-2032) & (k units) Table 137. North America Amyloidosis Therapeutics Sales Price by Application (2021-2026) & (US$/unit) Table 138. North America Amyloidosis Therapeutics Sales Price by Application (2027-2032) & (US$/unit) Table 139. North America Amyloidosis Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. North America Amyloidosis Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 141. North America Amyloidosis Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 142. North America Amyloidosis Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 143. North America Amyloidosis Therapeutics Sales by Country (2021-2026) & (k units) Table 144. North America Amyloidosis Therapeutics Sales by Country (2027-2032) & (k units) Table 145. North America Amyloidosis Therapeutics Sales Price by Country (2021-2026) & (US$/unit) Table 146. North America Amyloidosis Therapeutics Sales Price by Country (2027-2032) & (US$/unit) Table 147. United States Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 148. Canada Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 149. Mexico Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 150. Europe Amyloidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 151. Europe Amyloidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 152. Europe Amyloidosis Therapeutics Sales by Type (2021-2026) & (k units) Table 153. Europe Amyloidosis Therapeutics Sales by Type (2027-2032) & (k units) Table 154. Europe Amyloidosis Therapeutics Sales Price by Type (2021-2026) & (US$/unit) Table 155. Europe Amyloidosis Therapeutics Sales Price by Type (2027-2032) & (US$/unit) Table 156. Europe Amyloidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 157. Europe Amyloidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 158. Europe Amyloidosis Therapeutics Sales by Application (2021-2026) & (k units) Table 159. Europe Amyloidosis Therapeutics Sales by Application (2027-2032) & (k units) Table 160. Europe Amyloidosis Therapeutics Sales Price by Application (2021-2026) & (US$/unit) Table 161. Europe Amyloidosis Therapeutics Sales Price by Application (2027-2032) & (US$/unit) Table 162. Europe Amyloidosis Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Europe Amyloidosis Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 164. Europe Amyloidosis Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 165. Europe Amyloidosis Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 166. Europe Amyloidosis Therapeutics Sales by Country (2021-2026) & (k units) Table 167. Europe Amyloidosis Therapeutics Sales by Country (2027-2032) & (k units) Table 168. Europe Amyloidosis Therapeutics Sales Price by Country (2021-2026) & (US$/unit) Table 169. Europe Amyloidosis Therapeutics Sales Price by Country (2027-2032) & (US$/unit) Table 170. Germany Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 171. France Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 172. U.K. Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 173. Italy Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 174. Russia Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 175. Spain Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 176. Netherlands Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 177. Switzerland Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 178. Sweden Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 179. Poland Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 180. China Amyloidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 181. China Amyloidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 182. China Amyloidosis Therapeutics Sales by Type (2021-2026) & (k units) Table 183. China Amyloidosis Therapeutics Sales by Type (2027-2032) & (k units) Table 184. China Amyloidosis Therapeutics Sales Price by Type (2021-2026) & (US$/unit) Table 185. China Amyloidosis Therapeutics Sales Price by Type (2027-2032) & (US$/unit) Table 186. China Amyloidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 187. China Amyloidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 188. China Amyloidosis Therapeutics Sales by Application (2021-2026) & (k units) Table 189. China Amyloidosis Therapeutics Sales by Application (2027-2032) & (k units) Table 190. China Amyloidosis Therapeutics Sales Price by Application (2021-2026) & (US$/unit) Table 191. China Amyloidosis Therapeutics Sales Price by Application (2027-2032) & (US$/unit) Table 192. Asia Amyloidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 193. Asia Amyloidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 194. Asia Amyloidosis Therapeutics Sales by Type (2021-2026) & (k units) Table 195. Asia Amyloidosis Therapeutics Sales by Type (2027-2032) & (k units) Table 196. Asia Amyloidosis Therapeutics Sales Price by Type (2021-2026) & (US$/unit) Table 197. Asia Amyloidosis Therapeutics Sales Price by Type (2027-2032) & (US$/unit) Table 198. Asia Amyloidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 199. Asia Amyloidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 200. Asia Amyloidosis Therapeutics Sales by Application (2021-2026) & (k units) Table 201. Asia Amyloidosis Therapeutics Sales by Application (2027-2032) & (k units) Table 202. Asia Amyloidosis Therapeutics Sales Price by Application (2021-2026) & (US$/unit) Table 203. Asia Amyloidosis Therapeutics Sales Price by Application (2027-2032) & (US$/unit) Table 204. Asia Amyloidosis Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 205. Asia Amyloidosis Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 206. Asia Amyloidosis Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 207. Asia Amyloidosis Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 208. Asia Amyloidosis Therapeutics Sales by Country (2021-2026) & (k units) Table 209. Asia Amyloidosis Therapeutics Sales by Country (2027-2032) & (k units) Table 210. Asia Amyloidosis Therapeutics Sales Price by Country (2021-2026) & (US$/unit) Table 211. Asia Amyloidosis Therapeutics Sales Price by Country (2027-2032) & (US$/unit) Table 212. Japan Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 213. South Korea Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 214. India Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 215. Australia Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 216. Taiwan Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 217. Southeast Asia Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 218. SAMEA Amyloidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 219. SAMEA Amyloidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 220. SAMEA Amyloidosis Therapeutics Sales by Type (2021-2026) & (k units) Table 221. SAMEA Amyloidosis Therapeutics Sales by Type (2027-2032) & (k units) Table 222. SAMEA Amyloidosis Therapeutics Sales Price by Type (2021-2026) & (US$/unit) Table 223. SAMEA Amyloidosis Therapeutics Sales Price by Type (2027-2032) & (US$/unit) Table 224. SAMEA Amyloidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 225. SAMEA Amyloidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 226. SAMEA Amyloidosis Therapeutics Sales by Application (2021-2026) & (k units) Table 227. SAMEA Amyloidosis Therapeutics Sales by Application (2027-2032) & (k units) Table 228. SAMEA Amyloidosis Therapeutics Sales Price by Application (2021-2026) & (US$/unit) Table 229. SAMEA Amyloidosis Therapeutics Sales Price by Application (2027-2032) & (US$/unit) Table 230. SAMEA Amyloidosis Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 231. SAMEA Amyloidosis Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 232. SAMEA Amyloidosis Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 233. SAMEA Amyloidosis Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 234. SAMEA Amyloidosis Therapeutics Sales by Country (2021-2026) & (k units) Table 235. SAMEA Amyloidosis Therapeutics Sales by Country (2027-2032) & (k units) Table 236. SAMEA Amyloidosis Therapeutics Sales Price by Country (2021-2026) & (US$/unit) Table 237. SAMEA Amyloidosis Therapeutics Sales Price by Country (2027-2032) & (US$/unit) Table 238. Brazil Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 239. Argentina Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 240. Chile Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 241. Colombia Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 242. Peru Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 243. Saudi Arabia Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 244. Israel Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 245. UAE Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 246. Turkey Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 247. Iran Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 248. Egypt Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Table 249. Key Raw Materials Table 250. Raw Materials Key Suppliers Table 251. Amyloidosis Therapeutics Distributors List Table 252. Amyloidosis Therapeutics Customers List Table 253. Research Programs/Design for This Report Table 254. Authors List of This Report Table 255. Secondary Sources Table 256. Primary Sources List of Figures Figure 1. Amyloidosis Therapeutics Image Figure 2. Global Amyloidosis Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Amyloidosis Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Canakinumab Image Figure 5. CAEL-101 Image Figure 6. ALN-TTRsc02 Image Figure 7. ALN-ANG Image Figure 8. AG-10 Image Figure 9. Others Image Figure 10. Global Amyloidosis Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Amyloidosis Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 12. ATTR Amyloidoses Image Figure 13. AL Amyloidosis Image Figure 14. AA Amyloidoses Image Figure 15. Others Image Figure 16. Global Amyloidosis Therapeutics Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Figure 18. Global Amyloidosis Therapeutics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Amyloidosis Therapeutics Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Amyloidosis Therapeutics Revenue Market Share by Region (2021-2032) Figure 21. Global Amyloidosis Therapeutics Sales (2021-2032) & (k units) Figure 22. Global Amyloidosis Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 23. Global Amyloidosis Therapeutics Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico Amyloidosis Therapeutics Sales YoY (2021-2032) & (k units) Figure 25. Europe Amyloidosis Therapeutics Sales YoY (2021-2032) & (k units) Figure 26. China Amyloidosis Therapeutics Sales YoY (2021-2032) & (k units) Figure 27. Asia (Excluding China) Amyloidosis Therapeutics Sales YoY (2021-2032) & (k units) Figure 28. South America, Middle East and Africa Amyloidosis Therapeutics Sales YoY (2021-2032) & (k units) Figure 29. Global Amyloidosis Therapeutics Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Amyloidosis Therapeutics Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Amyloidosis Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Amyloidosis Therapeutics Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Amyloidosis Therapeutics Revenue Market Share by Type (2021-2032) Figure 35. Global Amyloidosis Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 36. Global Amyloidosis Therapeutics Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global Amyloidosis Therapeutics Sales Market Share by Type (2021-2032) Figure 38. Global Amyloidosis Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global Amyloidosis Therapeutics Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Amyloidosis Therapeutics Revenue Market Share by Application (2021-2032) Figure 41. Global Amyloidosis Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 42. Global Amyloidosis Therapeutics Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global Amyloidosis Therapeutics Sales Market Share by Application (2021-2032) Figure 44. North America Amyloidosis Therapeutics Revenue Share by Type (2021-2032) Figure 45. North America Amyloidosis Therapeutics Sales Share by Type (2021-2032) Figure 46. North America Amyloidosis Therapeutics Revenue Share by Application (2021-2032) Figure 47. North America Amyloidosis Therapeutics Sales Share by Application (2021-2032) Figure 48. North America Amyloidosis Therapeutics Revenue Share by Country (2021-2032) Figure 49. North America Amyloidosis Therapeutics Sales Share by Country (2021-2032) Figure 50. Europe Amyloidosis Therapeutics Revenue Share by Type (2021-2032) Figure 51. Europe Amyloidosis Therapeutics Sales Share by Type (2021-2032) Figure 52. Europe Amyloidosis Therapeutics Revenue Share by Application (2021-2032) Figure 53. Europe Amyloidosis Therapeutics Sales Share by Application (2021-2032) Figure 54. Europe Amyloidosis Therapeutics Revenue Share by Country (2021-2032) Figure 55. Europe Amyloidosis Therapeutics Sales Share by Country (2021-2032) Figure 56. China Amyloidosis Therapeutics Revenue Share by Type (2021-2032) Figure 57. China Amyloidosis Therapeutics Sales Share by Type (2021-2032) Figure 58. China Amyloidosis Therapeutics Revenue Share by Application (2021-2032) Figure 59. China Amyloidosis Therapeutics Sales Share by Application (2021-2032) Figure 60. Asia Amyloidosis Therapeutics Revenue Share by Type (2021-2032) Figure 61. Asia Amyloidosis Therapeutics Sales Share by Type (2021-2032) Figure 62. Asia Amyloidosis Therapeutics Revenue Share by Application (2021-2032) Figure 63. Asia Amyloidosis Therapeutics Sales Share by Application (2021-2032) Figure 64. Asia Amyloidosis Therapeutics Revenue Share by Country (2021-2032) Figure 65. Asia Amyloidosis Therapeutics Sales Share by Country (2021-2032) Figure 66. SAMEA Amyloidosis Therapeutics Revenue Share by Type (2021-2032) Figure 67. SAMEA Amyloidosis Therapeutics Sales Share by Type (2021-2032) Figure 68. SAMEA Amyloidosis Therapeutics Revenue Share by Application (2021-2032) Figure 69. SAMEA Amyloidosis Therapeutics Sales Share by Application (2021-2032) Figure 70. SAMEA Amyloidosis Therapeutics Revenue Share by Country (2021-2032) Figure 71. SAMEA Amyloidosis Therapeutics Sales Share by Country (2021-2032) Figure 72. Amyloidosis Therapeutics Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Amyloidosis Therapeutics Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Canakinumab
  • CAEL-101
  • ALN-TTRsc02
  • ALN-ANG
  • AG-10
  • Others
Applications
  • ATTR Amyloidoses
  • AL Amyloidosis
  • AA Amyloidoses
  • Others
Companies covered
  • Pfizer Inc.
  • GlaxoSmithKline Plc
  • SOM Innovation Biotech SL
  • Prothena Corporation Plc
  • ProteoTech, Inc.
  • Onyx Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Isis Pharmaceuticals, Inc.
  • Celgene Corporation
  • Bsim2
  • Bellus Health Inc.
  • Arcturus Therapeutics, Inc
  • Alnylam Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Amyloidosis Therapeutics Market by Type
  3. 1.2.1 Global Amyloidosis Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Canakinumab
  5. 1.2.3 CAEL-101
  6. 1.2.4 ALN-TTRsc02
  7. 1.2.5 ALN-ANG
  8. 1.2.6 AG-10
  9. 1.2.7 Others
  10. 1.3 Amyloidosis Therapeutics Market by Application
  11. 1.3.1 Global Amyloidosis Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 ATTR Amyloidoses
  13. 1.3.3 AL Amyloidosis
  14. 1.3.4 AA Amyloidoses
  15. 1.3.5 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Amyloidosis Therapeutics Market Dynamics
  1. 2.1 Amyloidosis Therapeutics Industry Trends
  2. 2.2 Amyloidosis Therapeutics Industry Drivers
  3. 2.3 Amyloidosis Therapeutics Industry Opportunities and Challenges
  4. 2.4 Amyloidosis Therapeutics Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Amyloidosis Therapeutics Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Amyloidosis Therapeutics Revenue by Region
  3. 3.2.1 Global Amyloidosis Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Amyloidosis Therapeutics Revenue by Region (2021-2026)
  5. 3.2.3 Global Amyloidosis Therapeutics Revenue by Region (2027-2032)
  6. 3.2.4 Global Amyloidosis Therapeutics Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Amyloidosis Therapeutics Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Amyloidosis Therapeutics Sales by Region
  9. 3.4.1 Global Amyloidosis Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Amyloidosis Therapeutics Sales by Region (2021-2026)
  11. 3.4.3 Global Amyloidosis Therapeutics Sales by Region (2027-2032)
  12. 3.4.4 Global Amyloidosis Therapeutics Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Amyloidosis Therapeutics Revenue by Manufacturers
  2. 4.1.1 Global Amyloidosis Therapeutics Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Amyloidosis Therapeutics Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Amyloidosis Therapeutics Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Amyloidosis Therapeutics Sales by Manufacturers
  6. 4.2.1 Global Amyloidosis Therapeutics Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Amyloidosis Therapeutics Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Amyloidosis Therapeutics Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Amyloidosis Therapeutics Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Amyloidosis Therapeutics Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Amyloidosis Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Amyloidosis Therapeutics Manufacturers, Product Type & Application
  13. 4.7 Global Amyloidosis Therapeutics Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Amyloidosis Therapeutics Market CR5 and HHI
  16. 4.8.2 2025 Amyloidosis Therapeutics Tier 1, Tier 2, and Tier 3
5 Amyloidosis Therapeutics Market by Type
  1. 5.1 Global Amyloidosis Therapeutics Revenue by Type
  2. 5.1.1 Global Amyloidosis Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Amyloidosis Therapeutics Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Amyloidosis Therapeutics Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Amyloidosis Therapeutics Sales by Type
  6. 5.2.1 Global Amyloidosis Therapeutics Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Amyloidosis Therapeutics Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Amyloidosis Therapeutics Sales Market Share by Type (2021-2032)
  9. 5.3 Global Amyloidosis Therapeutics Price by Type
6 Amyloidosis Therapeutics Market by Application
  1. 6.1 Global Amyloidosis Therapeutics Revenue by Application
  2. 6.1.1 Global Amyloidosis Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Amyloidosis Therapeutics Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Amyloidosis Therapeutics Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Amyloidosis Therapeutics Sales by Application
  6. 6.2.1 Global Amyloidosis Therapeutics Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Amyloidosis Therapeutics Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Amyloidosis Therapeutics Sales Market Share by Application (2021-2032)
  9. 6.3 Global Amyloidosis Therapeutics Price by Application
7 Company Profiles
  1. 7.1 Pfizer Inc.
  2. 7.1.1 Pfizer Inc. Company Information
  3. 7.1.2 Pfizer Inc. Business Overview
  4. 7.1.3 Pfizer Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Inc. Amyloidosis Therapeutics Product Portfolio
  6. 7.1.5 Pfizer Inc. Recent Developments
  7. 7.2 GlaxoSmithKline Plc
  8. 7.2.1 GlaxoSmithKline Plc Company Information
  9. 7.2.2 GlaxoSmithKline Plc Business Overview
  10. 7.2.3 GlaxoSmithKline Plc Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 GlaxoSmithKline Plc Amyloidosis Therapeutics Product Portfolio
  12. 7.2.5 GlaxoSmithKline Plc Recent Developments
  13. 7.3 SOM Innovation Biotech SL
  14. 7.3.1 SOM Innovation Biotech SL Company Information
  15. 7.3.2 SOM Innovation Biotech SL Business Overview
  16. 7.3.3 SOM Innovation Biotech SL Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 SOM Innovation Biotech SL Amyloidosis Therapeutics Product Portfolio
  18. 7.3.5 SOM Innovation Biotech SL Recent Developments
  19. 7.4 Prothena Corporation Plc
  20. 7.4.1 Prothena Corporation Plc Company Information
  21. 7.4.2 Prothena Corporation Plc Business Overview
  22. 7.4.3 Prothena Corporation Plc Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Prothena Corporation Plc Amyloidosis Therapeutics Product Portfolio
  24. 7.4.5 Prothena Corporation Plc Recent Developments
  25. 7.5 ProteoTech, Inc.
  26. 7.5.1 ProteoTech, Inc. Company Information
  27. 7.5.2 ProteoTech, Inc. Business Overview
  28. 7.5.3 ProteoTech, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 ProteoTech, Inc. Amyloidosis Therapeutics Product Portfolio
  30. 7.5.5 ProteoTech, Inc. Recent Developments
  31. 7.6 Onyx Pharmaceuticals, Inc.
  32. 7.6.1 Onyx Pharmaceuticals, Inc. Company Information
  33. 7.6.2 Onyx Pharmaceuticals, Inc. Business Overview
  34. 7.6.3 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
  36. 7.6.5 Onyx Pharmaceuticals, Inc. Recent Developments
  37. 7.7 Millennium Pharmaceuticals, Inc.
  38. 7.7.1 Millennium Pharmaceuticals, Inc. Company Information
  39. 7.7.2 Millennium Pharmaceuticals, Inc. Business Overview
  40. 7.7.3 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
  42. 7.7.5 Millennium Pharmaceuticals, Inc. Recent Developments
  43. 7.8 Isis Pharmaceuticals, Inc.
  44. 7.8.1 Isis Pharmaceuticals, Inc. Company Information
  45. 7.8.2 Isis Pharmaceuticals, Inc. Business Overview
  46. 7.8.3 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
  48. 7.8.5 Isis Pharmaceuticals, Inc. Recent Developments
  49. 7.9 Celgene Corporation
  50. 7.9.1 Celgene Corporation Company Information
  51. 7.9.2 Celgene Corporation Business Overview
  52. 7.9.3 Celgene Corporation Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Celgene Corporation Amyloidosis Therapeutics Product Portfolio
  54. 7.9.5 Celgene Corporation Recent Developments
  55. 7.10 Bsim2
  56. 7.10.1 Bsim2 Company Information
  57. 7.10.2 Bsim2 Business Overview
  58. 7.10.3 Bsim2 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Bsim2 Amyloidosis Therapeutics Product Portfolio
  60. 7.10.5 Bsim2 Recent Developments
  61. 7.11 Bellus Health Inc.
  62. 7.11.1 Bellus Health Inc. Company Information
  63. 7.11.2 Bellus Health Inc. Business Overview
  64. 7.11.3 Bellus Health Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Bellus Health Inc. Amyloidosis Therapeutics Product Portfolio
  66. 7.11.5 Bellus Health Inc. Recent Developments
  67. 7.12 Arcturus Therapeutics, Inc
  68. 7.12.1 Arcturus Therapeutics, Inc Company Information
  69. 7.12.2 Arcturus Therapeutics, Inc Business Overview
  70. 7.12.3 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Portfolio
  72. 7.12.5 Arcturus Therapeutics, Inc Recent Developments
  73. 7.13 Alnylam Pharmaceuticals, Inc.
  74. 7.13.1 Alnylam Pharmaceuticals, Inc. Company Information
  75. 7.13.2 Alnylam Pharmaceuticals, Inc. Business Overview
  76. 7.13.3 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
  78. 7.13.5 Alnylam Pharmaceuticals, Inc. Recent Developments
8 North America
  1. 8.1 North America Amyloidosis Therapeutics Market Size by Type
  2. 8.1.1 North America Amyloidosis Therapeutics Revenue by Type (2021-2032)
  3. 8.1.2 North America Amyloidosis Therapeutics Sales by Type (2021-2032)
  4. 8.1.3 North America Amyloidosis Therapeutics Price by Type (2021-2032)
  5. 8.2 North America Amyloidosis Therapeutics Market Size by Application
  6. 8.2.1 North America Amyloidosis Therapeutics Revenue by Application (2021-2032)
  7. 8.2.2 North America Amyloidosis Therapeutics Sales by Application (2021-2032)
  8. 8.2.3 North America Amyloidosis Therapeutics Price by Application (2021-2032)
  9. 8.3 North America Amyloidosis Therapeutics Market Size by Country
  10. 8.3.1 North America Amyloidosis Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Amyloidosis Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Amyloidosis Therapeutics Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Amyloidosis Therapeutics Market Size by Type
  2. 9.1.1 Europe Amyloidosis Therapeutics Revenue by Type (2021-2032)
  3. 9.1.2 Europe Amyloidosis Therapeutics Sales by Type (2021-2032)
  4. 9.1.3 Europe Amyloidosis Therapeutics Price by Type (2021-2032)
  5. 9.2 Europe Amyloidosis Therapeutics Market Size by Application
  6. 9.2.1 Europe Amyloidosis Therapeutics Revenue by Application (2021-2032)
  7. 9.2.2 Europe Amyloidosis Therapeutics Sales by Application (2021-2032)
  8. 9.2.3 Europe Amyloidosis Therapeutics Price by Application (2021-2032)
  9. 9.3 Europe Amyloidosis Therapeutics Market Size by Country
  10. 9.3.1 Europe Amyloidosis Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Amyloidosis Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Amyloidosis Therapeutics Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Amyloidosis Therapeutics Market Size by Type
  2. 10.1.1 China Amyloidosis Therapeutics Revenue by Type (2021-2032)
  3. 10.1.2 China Amyloidosis Therapeutics Sales by Type (2021-2032)
  4. 10.1.3 China Amyloidosis Therapeutics Price by Type (2021-2032)
  5. 10.2 China Amyloidosis Therapeutics Market Size by Application
  6. 10.2.1 China Amyloidosis Therapeutics Revenue by Application (2021-2032)
  7. 10.2.2 China Amyloidosis Therapeutics Sales by Application (2021-2032)
  8. 10.2.3 China Amyloidosis Therapeutics Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Amyloidosis Therapeutics Market Size by Type
  2. 11.1.1 Asia Amyloidosis Therapeutics Revenue by Type (2021-2032)
  3. 11.1.2 Asia Amyloidosis Therapeutics Sales by Type (2021-2032)
  4. 11.1.3 Asia Amyloidosis Therapeutics Price by Type (2021-2032)
  5. 11.2 Asia Amyloidosis Therapeutics Market Size by Application
  6. 11.2.1 Asia Amyloidosis Therapeutics Revenue by Application (2021-2032)
  7. 11.2.2 Asia Amyloidosis Therapeutics Sales by Application (2021-2032)
  8. 11.2.3 Asia Amyloidosis Therapeutics Price by Application (2021-2032)
  9. 11.3 Asia Amyloidosis Therapeutics Market Size by Country
  10. 11.3.1 Asia Amyloidosis Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Amyloidosis Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Amyloidosis Therapeutics Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Amyloidosis Therapeutics Market Size by Type
  2. 12.1.1 SAMEA Amyloidosis Therapeutics Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Amyloidosis Therapeutics Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Amyloidosis Therapeutics Price by Type (2021-2032)
  5. 12.2 SAMEA Amyloidosis Therapeutics Market Size by Application
  6. 12.2.1 SAMEA Amyloidosis Therapeutics Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Amyloidosis Therapeutics Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Amyloidosis Therapeutics Price by Application (2021-2032)
  9. 12.3 SAMEA Amyloidosis Therapeutics Market Size by Country
  10. 12.3.1 SAMEA Amyloidosis Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Amyloidosis Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Amyloidosis Therapeutics Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Amyloidosis Therapeutics Value Chain Analysis
  2. 13.1.1 Amyloidosis Therapeutics Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Amyloidosis Therapeutics Production Mode & Process
  6. 13.2 Amyloidosis Therapeutics Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Amyloidosis Therapeutics Distributors
  9. 13.2.3 Amyloidosis Therapeutics Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst